D elirium in the intensive care unit (ICU) is prevalent, [1] [2] [3] [4] [5] [6] with both delirium duration and severity associated with mortality. [6] [7] [8] [9] [10] In a prospective cohort study of 304 ICU patients, duration of delirium was associated with a higher 1-year mortality after adjusting for relevant covariates. 6 Similarly, patients with high delirium severity had higher mortality during hospital stay and at 3 and 12 months after discharge. 9, 10 Delirium is a complex pathophysiological process explained through a multifactorial model. 11 The model posits a dynamic interrelationship between preexisting vulnerability and the therapeutic and iatrogenic insults acquired during hospitalization. 11 The interaction between the vulnerability and insult factors 12 produces a final common neurotransmission
From the *Department of Biostatistics, Indiana University School of Medicine; **Department of Psychiatry, Indiana University School of Medicine; † Indiana University Center for Aging Research, Indianapolis, Indiana; state of relative or absolute cholinergic deficiency, dopaminergic excess, and γ-aminobutyric acid (GABA) overload. [13] [14] [15] Based on the neurotransmitter model for delirium, we developed a bundle for pharmacological management of delirium (PMD), 16 with the aim of reducing exposure to benzodiazepines and anticholinergics and prescribing lowdose haloperidol. We conducted a randomized controlled pragmatic trial to test the effectiveness of our PMD bundle among ICU patients. Our primary hypothesis was that ICU patients receiving the PMD bundle would have (1) higher number of hospital days without delirium or coma and (2) reduced delirium severity at 1-week postrandomization or hospital discharge.
MATERIALS AND METHODS
The local Institutional Review Board approved the study, and patients' legally authorized representatives provided informed consent.
Study Setting
We enrolled patients admitted to the ICU services of three Indianapolis hospitals from February 2009 to January 2015. Eskenazi Hospital is a 457-bed public hospital with an 8-bed surgical ICU (SICU), a 14-bed medical ICU (MICU), and a 29-bed progressive/step-down ICU. University Hospital is a 257-bed tertiary care hospital with 36 MICU and SICU beds. Methodist Hospital is an 802-bed tertiary center with 65 MICU and SICU beds.
Eligibility and Randomization
Inclusion criteria were: (1) patients admitted to the ICU for 24 hours or more, (2) aged 18 years or older, (3) screen positive for delirium based on the Richmond AgitationSedation Scale (RASS) 17 and the Confusion Assessment Method for the ICU (CAM-ICU) 18 on any day during the ICU stay, and (4) English speaking. Exclusion criteria were: (1) history of severe mental illness, (2) Axis 1 psychiatric disorder, (3) severe cognitive impairment preventing study assessments, (4) alcohol-related delirium, (5) aphasic stroke or traumatic brain injury, (6) history of allergic reaction or contraindication to haloperidol, (7) withdrawal of life support, (8) pregnant or nursing, (9) legally blind or deaf, (10) admission for suicide attempt, (11) corrected QT interval (QTc) greater than 500 milliseconds, or (12) previously enrolled in the PMD study or enrolled in another study. Randomization occurred in a 1:1 ratio between the PMD bundle and the usual care groups utilizing a computergenerated allocation in random blocks of four stratified by enrollment site.
PMD Bundle Content
The PMD bundle consisted of a multicomponent intervention targeting the imbalance of three neurotransmitters (acetylcholine, dopamine, and GABA), implemented postrandomization. 16 The bundle focused on reducing exposure to 20 definite anticholinergic medications identified by the Anticholinergic Cognitive Burden Scale;
19-21 reducing exposure to benzodiazepines 22 ; and prescribing low-dose haloperidol.
Delivery of the PMD Bundle
The reduction in exposure to anticholinergic medications was executed through both computerized decision support and a human clinical expert, a pharmacist. The computerized physician order entry generated automated interruptive messages that alerted providers to the risks of anticholinergics in delirium and offered alternative, nonanticholinergic medications. Ignoring the recommendation prompted the study pharmacist to contact the provider on the same day to discuss reducing or discontinuing the anticholinergic medication. The 20 definite anticholinergics targeted are available in Supplementary Table S1 . Benzodiazepine reduction was achieved through communications between the ICU teams and the study pharmacist. The goal was to achieve 20% to 40% dose reduction on day 1 with subsequent reductions of 10% to 25% every 24 hours. Patients aged 60 years or older received 0.5 mg of haloperidol, whereas patients younger than 60 years received 1 mg every 8 hours intravenously for a total of 7 days or until discharged from the hospital, whichever came first. Haloperidol was administered only if the QTc was less than 500 ms. In contrast to the haloperidol component, the other two PMD bundle components (anticholinergic reduction and benzodiazepine reduction) continued throughout the hospital stay for up to 30 days.
Usual Care
Usual care group received no electronic or human decision support for PMD throughout their hospital stay. With our pragmatic design, participants in usual care could receive haloperidol as part of routine care, without restriction on the dose, frequency, or duration.
Primary Outcomes

Delirium/Coma-Free Days
Delirium/coma-free days were defined as number of days after randomization patient was alive free of delirium and not in coma. This outcome describes the duration of normal cognitive status where the patient is not comatose and does not have delirium. Patients with a RASS score of −4 or −5 with lack of response to verbal or physical stimuli were characterized as comatose and ineligible for CAM-ICU assessments. Patients with a RASS score of −3 to 4 were considered eligible for CAM-ICU assessments. The CAM-ICU score was determined by examining the patient for (a) acute or fluctuating changes in mental status, (b) inattention, (c) altered level of consciousness, and (d) disorganized thinking. Patients were considered delirious if they displayed (a) and (b), plus (c) and/or (d).
Delirium Severity
Delirium severity was assessed using the Delirium Rating Scale-Revised-98 (DRS-R-98) 23 and CAM-ICU-7. 24 DRS-R-98 is a 16-item scale with 13 severity items (rated 0-3; maximum, 39 points), with higher scores indicating greater delirium severity. 23 CAM-ICU-7 is a seven-point scale (0-7), derived from the RASS and the CAM-ICU. The CAM-ICU-7 score ranges from 0 to 7, categorized as 0 to 2, no delirium; 3 to 5, mild to moderate delirium; and 6 to 7, severe delirium. 24 Trained research assistants blinded to randomization assignment conducted twice-daily RASS, CAM-ICU, CAM-ICU-7, and DRS-R-98 assessments after 24 hours of ICU admission until patients' discharge from the hospital or death.
Secondary Outcomes
In-hospital and 30-day posthospital discharge mortality rates, ICU and hospital lengths of stay, and delirium-related hospital complications 4, 25 were collected through electronic records and direct daily observation.
Other Data
Demographics, cognitive function, 26 activities and instrumental activities of daily living, 27, 28 admission diagnoses, severity of illness, 29 chronic comorbidities, 30 and medications were collected (Details in Supplementary Material).
Adverse Events
QT prolongation (QTc greater than 500 ms) and extrapyramidal and movement-related symptoms were reported to an independent Data Safety Monitoring Board (DSMB) throughout the study (Details in Supplementary Material).
Data Analyses
Baseline differences between groups were assessed using Fisher's exact test for categorical outcomes and Wilcoxon ranksum (also known as Mann-Whitney U) test for continuous measures since the majority of these measures contained skewed data. Additionally, we used the Fisher's exact test to compare the percentage of patients who received targeted medications, complications, and adverse events. To test for difference in the number of adverse events and dose (total and daily) between the randomized groups, we used the Wilcoxon rank-sum test.
We conducted intention-to-treat analyses to test the intervention effects on the primary and secondary outcomes. Six patients withdrew from the trial, and their data collected up to the date of withdrawal were included in the analyses. Delirium/coma-free days and length of stay were compared using the nonparametric Wilcoxon rank-sum test. Two time points were used for delirium/coma-free days and delirium severity: day 8 postrandomization as this time was the end of the haloperidol use in the intervention group, and day 30 postrandomization as this was the end of active delirium monitoring. Patients who died or withdrew before day 8 or 30 had their subsequent delirium/coma-free days counted as 0. Patients who were discharged alive before day 8 or 30 had the remaining days counted as delirium/coma free.
Since delirium severity measured by DRS-R-98 had substantial missing values, we used multiple imputation methods to compare change in DRS-R-98 scores from baseline to day 8 or hospital discharge (Details in Supplementary Material). Mixed-effects model with mean daily CAM-ICU-7 scores as the dependent variable was used to compare the difference in CAM-ICU-7 change scores from baseline to day 8 or hospital discharge. The mixed model included randomization group, time, and group and time interaction as independent variables and a random effect for patients.
We used Fisher's exact tests to examine differences in mortality in ICU, before hospital discharge, and 30 days post hospital discharge. Logistic regression models were also used to determine group differences in hospital mortality and mortality 30 days post hospital discharge, adjusting for baseline variables. Length of stay was compared using the nonparametric Wilcoxon rank-sum test. Additionally, we used proportional hazard models to test the effect of the intervention on time to discharge with a competing risk for death. Patients who withdrew were censored at date of study withdrawal. All analyses were conducted using SAS v9.4.
Sample Size and Power Consideration
The trial had a planned enrollment of 428 patients with the anticipated sample size of 400 patients completing follow-up, thus providing 80% power to detect an effect size of 0.286 between the intervention and control groups in the primary outcomes of delirium severity or delirium/coma-free days at 0.05 significance level. Enrollment was stopped in year 5 of the trial due to the end of funding. The final enrollment of 351 patients provides 76% power for detecting the effect size assumed in the original power estimate. The DSMB approved the reduction in sample size.
RESULTS
Participant Characteristics
From February 2009 to January 2015, 12,402 patients were screened and 351 were enrolled (Eskenazi Hospital, n = 324; University Hospital, n = 23; Methodist Hospital, n = 4). Patients were randomly assigned to the PMD intervention (n = 174) or usual care groups (n = 177) ( Figure 1 ). The mean age was 59.3 years (SD = 16.9 years), 52% were females, and 42% were African American. Patients had a mean Acute Physiology and Chronic Health Evaluation-II score of 19.3 (SD = 8.1) and a mean Charlson Comorbidity Index score of 3.2 (SD = 3.0). The majority of patients were admitted to the MICU services (63%), received mechanical ventilation for at least 1 day (73%), and had sepsis and/or acute respiratory failure as the principal admitting diagnosis (52%). The two randomized groups had similar demographics, severity of illness, chronic comorbidities, prior functional and cognitive status, and admitting diagnoses (Table 1) .
Primary Outcomes
There were no significant differences in median delirium/ coma-free days at day 8 (Figure 2 ). There were no significant differences for decrease in delirium severity at day 8 on either DRS-R-98 or CAM-ICU-7. At hospital discharge, the intervention group showed a greater reduction in delirium severity, as measured by the CAM-ICU-7 (mean decrease in CAM-ICU-7 score for PMD vs usual care Table S2 ). There were no significant differences for decrease in delirium severity at day 8 or at hospital discharge. Similar results were observed in patients aged 75 years or older (Supplementary Table S3 ).
Secondary Outcomes
Mortality at both hospital discharge (PMD, 11.5%; usual care, 18.1%; P = .098; odds ratio [OR] = 0.61 (95% CI 0.32-1.16)) and 30-day posthospital discharge (PMD, 14.6%; usual care, 22%; P = .096; OR = 0.62 (95% CI 0.35-1.12)) was not significantly different between the two groups (Supplementary Table S4 usual care = 58 [40.3%]; P = .198) and no differences in delirium-related hospital complication rates between the two groups ( Table 2) . When results were limited to patients aged 65 years or older and 75 years or older, no differences were observed in any of the secondary outcomes (Supplementary  Tables S2 and S3 ). Table 3 describes the use of haloperidol, benzodiazepines, and anticholinergics classified as prerandomization, day of randomization, and postrandomization periods in both groups. PMD bundle delivery increased the exposure to low-dose haloperidol postrandomization as 68% of the PMD group received at least one dose of haloperidol vs 32% of the usual care group (P < .001). Benzodiazepine median daily exposure was lower postrandomization in the PMD group but did not reach statistical significance (P = .079). No significant differences in the proportion of participants receiving strong anticholinergics were identified (P = .248). Prior to randomization, there were no differences in the exposure to haloperidol, benzodiazepines, and anticholinergics. The administration of other antipsychotics did not differ between groups (Table 3) . There were also no differences in exposure to sedatives and antipsychotics prior to extubation postrandomization (Supplementary Table S5 ).
Process Measures
Adverse Events
The rates of serious adverse events were not different between groups (PMD = 44 patients [ Table S6 ).
None of the events were definitely or probably related to the protocol, as determined by the DSMB.
Other Analyses
Online Supplementary Material contains ancillary analyses: per-protocol analyses, proportional hazards model for time to hospital discharge with competing risk of death, and intervention-targeted medication exposures (Supplementary  Tables S7-S9 ). Per-protocol analyses limited to subjects with haloperidol exposure in the intervention group showed results similar to the intention-to-treat analysis (Supplementary  Table S7 ). Proportional hazards model for time to hospital discharge with competing risk of death showed that PMD group did not differ from usual care in time to discharge (hazard ratio = 1.08 [95% CI 0.86-1.35]) (Supplementary Table S8 ).
DISCUSSION
Our pragmatic randomized controlled trial showed that a multicomponent PMD bundle was not effective in reducing delirium duration and delirium severity at 1-week postrandomization. The PMD bundle included a combination of deprescribing benzodiazepines and anticholinergics and prescribing low-dose haloperidol. The adherence to the bundle was accomplished by a computerized decision support coupled with a pharmacist. The PMD trial results are the first to describe the effects of implementing a complex pharmacologic intervention to reduce delirium duration and severity in the ICU. As the intervention was not able to achieve a significant reduction in benzodiazepines and anticholinergics, we cannot ascertain with confidence that the 3 Instrumental activities of daily living assessed by Lawton Scale. 4 Other includes cardiovascular and gastrointestinal diagnoses.
JAGS MAY 2019-VOL. 67, NO. 5 THE PMD RANDOMIZED CLINICAL TRIALbundle is truly ineffective in delirium reduction and whether our results could have been different if we had achieved high fidelity in all three components of the bundle. Additionally, given the low anticholinergic burden in the ICU, this component of the bundle may not be a viable intervention target in future studies.
Our results further expand the findings of the Hope-ICU, 31 MIND (Modifying the Impact of ICU-Induced Neurological Dysfunction), 32 and REDUCE 33 trials. Some differences are worthy to note: Hope-ICU and MIND both tested higher doses of haloperidol, whereas REDUCE used prophylactic low-dose haloperidol with one of the secondary outcomes being delirium/coma-free days. The aforementioned trials tested haloperidol as a sole intervention compared to placebo or another antipsychotic. [31] [32] [33] Rather than focusing on just the dopaminergic pathway, we targeted two additional neurotransmitter imbalances in the cholinergic and the GABA systems. As delirium is a complex pathophysiological process, we hypothesized that a combined approach might be better suited to reduce delirium. The PMD bundle did improve delirium severity at discharge, but our process measures did not show a discernible difference in the components intervened. Hence, we can only speculate that continuing the PMD bundle may result in positive outcomes later in the hospital course.
The PMD bundle did not decrease the risk of death and lengths of ICU and hospital stay, nor did it reduce the duration of mechanical ventilation, findings similar to other pharmacologic delirium trials in the ICU setting. [31] [32] [33] To improve these outcomes, system-wide changes could be required in addition to the pharmacological approaches to delirium. Programs employing six or more implementation strategies targeting delirium assessment, prevention, and treatment with integration of the pain, agitation, and delirium guidelines 22 or the ABCDE bundle 34 (Awakening and Breathing coordination, Choice of sedation, Delirium monitoring, and Early Mobility) may be better suited to improve ICU length of stay. 35 It has been proposed that haloperidol may have direct neuroprotective and immunomodulatory effects, and combined with its dopamine blockade activities, it stands to reason that haloperidol could be efficacious in reducing delirium. [36] [37] [38] [39] This may explain the positive results, as seen in the study by Wang et al, using low-dose haloperidol among SICU patients. 36 The patient population in that study was not as critically ill as expected in a traditional MICU or SICU. The high severity of illness, as seen in our study and the aforementioned ICU trials, [31] [32] [33] may render it difficult to control delirium symptoms with a single agent without managing other mechanistic pathways involved in delirium pathophysiology. Even though we focused on three neurotransmitter pathways (ie, dopaminergic, cholinergic, and GABA), we still could not reduce delirium duration and severity. Future interventions incorporating advancements in delirium pathophysiology might be better suited to reduce critical illness delirium.
Our study had limitations. This was a single-city study conducted in academic hospitals. Some patients received intervention after 48 hours postrandomization that may . Patients who received the drug during hospitalization. 3 Benzodiazepine data presented as lorazepam equivalents. 4 Anticholinergic burden measured by Anticholinergic Burden Scale. 5 Opioid data presented as morphine equivalents.
JAGS MAY 2019-VOL. 67, NO. 5 THE PMD RANDOMIZED CLINICAL TRIALhave reduced the intervention efficacy. We were not able to enroll the planned sample size. From 2009 to 2015, the prevalence of delirium decreased at our institute for unclear reasons. It could have been due to a change in sedation, analgesia practices, and implementation of brain care bundles. This also highlights the difficulties in conducting ICU studies. We did not have a placebo-controlled arm. Due to our patient-based randomization instead of provider-based randomization, contamination may have happened between study groups, with same physicians taking care of patients in both the arms whose prescribing practices may have been influenced by the study. Utilizing an electronic medical record system for generating computer alerts and the incorporation of a pharmacist to ensure bundle adherence may not be generalizable to other institutions or cost-effective. Strategies to overcome the limitations of PMD that can be employed in future trials could include conducting a placebo-controlled double-blind trial with a delirium rescue protocol to reduce use of antipsychotic exposure or a cluster-randomized trial with interventions focused on ICU units rather than individual patients that may reduce contamination across arms. The study had several strengths. We had a diverse patient population. Trained research staff assessed sedation and delirium twice daily. Our bundle focused on three neurotransmitter imbalances. We also targeted delirium severity, which few studies have reported. We used a practical delivery method, providing recommendations at the time of order entry, suitable for a fast-paced ICU environment.
In conclusion, implementation of a multicomponent pharmacological bundle of deprescribing deliriogenic medications coupled with prescribing low-dose haloperidol does not reduce delirium burden among critically ill patients.
